Table 1.
Contribution of BM-derived EC in tumor neovessels in various studies
| Ref. | Tumor model | Tumor stage | % of contribution |
BM tracking | EC Marker | BM-EC detection |
No. of BM cells transplanted |
|
|---|---|---|---|---|---|---|---|---|
| Asahara et al 1999 | Colon Cancer (MCA 38) s.c. | 1–3 weeks | positive | Flk-lacZ or Tie2-LacZ | IHC | 2×106 BM mononuclear cells | ||
| Lyden et al. 2001 | Lymphoma cell (B6RV2) s.c. | 2 weeks | 90% | Rosa26-LacZ | vWF | IHC | 1×106 BM mononuclear cells | |
| Davidoff et al. 2001 | Neuroblasma cell (NXS2) s.c. | - | 5% | BM cells transduced with MSCV-tsFIk-l-I-GFP | CD31 and CD34 | IF | 2×106 modified BM cells without RBC | |
| Reyes et al. 2002 | Lewis Lung Carcinoma (LLC) s.c. | 2 weeks | 35% | Human β2-microglobulin | CD31 and vWF | IF | 0.25×106 human MAPC–derived endothelial cells | |
| De Palma et al. 2003 | LLC, s.c., Melanoma (B16) s.c. | Late stage | neg | Tie2-GFP | CD31 | IF, 3D microscopy | 1×106 Lin− BM cells | |
| Garcia-Barros et al. 2003 | Fibrosarcomas (MCA/129) s.c. | 2 weeks | 50% | Rosa26-LacZ | vWF | IHC | 1×107 BM cells | |
| Ruzinova et al. 2003 | Pten+/− mouse | Uterine carcinoma | spontaneous | 16% | Rosa26-LacZ | CD31 | IHC | 1×106 BM mononuclear cells |
| lymph hyperplasia | neg | |||||||
| Dwenger et al. 2004 | MMTV-PyMT mouse | 10–12 week s | 1.3% | Rosa26-LacZ | CD31 | IHC | 2–5×106 BM cells | |
| Rajantie et al. 2004 | B16F1 s.c. | 2–3 weeks | neg | Actb-GFP | CD31 and vWF | IF | 2×106 BM cells | |
| Goethert et al. 2004 | LLC s.c., B6RV2 s.c. | 2 weeks | neg | Endothelial-SCL-Cre-ER× R26R or R26R-EYFP | CD31 | IHC, FACS | 2×106 BM cells | |
| Spring et al. 2005 | RIP1-Tag5 mice AlbTag | 10–16 weeks | 3–38% | Tie2Cre×RAGE-EGFP | Lectin-perfusion, CD31 | IF, FACS | 2×106 BM cells | |
| Peters et al. 2005 | Various human tumors | - | 1–12% | X or Y Chromosome | vWF | FISH | ||
| Duda et al. 2006 | LLC s.c., B16 s.c., Breast cancer cell (MCa8) orth. | - | <1% | Actb-GFP, Tie2-GFP | CD31 | IF, FACS | 5×106 BM cells | |
| Nolan et al. 2007 | LLC s.c., B16F0 (ortho); MMTV-PYMT mouse | Several time points in first 2 weeks | 2–20% | Actb-GFP | CD31, VE-cadh, Lectin-perfusion | FACS, 3D microscopy | 1×107 BM cells | |
| Gao et al. 2008 | LLC s.c., MMTV-PYMT mouse | Lung metastasis | 12% | Actb-GFP | CD31 | IF, FACS | 1×107 BM cells | |
| Purhonen et al. 2008 | B16 s.c. | 2–3 weeks | neg | Actb-GFP, VEGFR2-LacZ | CD31, vWF | IF | 7×106 BM cells | |
s.c.: subcutaneous injection; ortho.: orthotropic injection; IF:immunofluorescence; IHC: immunohistochemistry; FACS: flouorescent activated cell sorting; neg: negative; RAGE: receptor for advanced glycated end products